John C. McKew

TL;DR: Evaluation of recently approved new drugs has revealed that the number of approved drugs discovered through phenotypic screens, an original drug screening paradigm, has exceeded those discovered through the molecular target-based approach.

TL;DR: This open-label, dose-escalation phase 1-2a study gave monthly intrathecal HPβCD to participants with NPC1 with neurological manifestation at the National Institutes of Health and evaluated Serum and CSF 24(S)-hydroxycholesterol (24[S]-HC), which serves as a biomarker of target engagement, andCSF protein biomarkers were evaluated.

TL;DR: The identification of 53 drugs with activity of blocking Ebola VLP entry into cells are reported, including microtubule inhibitors, estrogen receptor modulators, antihistamines, antipsychotics, pump/channel antagonists, and anticancer/antibiotics.

TL;DR: In this article, novel compounds are disclosed which inhibit the activity of cytosolic phospholipase A2, and pharmaceutical compositions comprising such compounds and methods of treatment using such compositions are also disclosed.

TL;DR: T-863, a potent DGAT1 inhibitor acting on the acyl-CoA binding site of DGat1, decreased body weight, improved insulin sensitivity, and alleviated hepatic steatosis in diet-induced obese mice, and suggests that pharmacological inhibition of DG AT1 holds promise in treating diverse metabolic disorders.